(Reuters) - Shares of Vivus rose almost 10 percent in pre-market trade to $6.03, while those of KV were up about 3.5 percent, amid thin trade, at $28.10.
KV bought the U.S. marketing rights for the product, Evamist, from California-based Vivus earlier this year. The agreement required KV to pay $140 million in cash upon the approval of Evamist's new drug application.
Read more at Reuters.com Government Filings News
KV bought the U.S. marketing rights for the product, Evamist, from California-based Vivus earlier this year. The agreement required KV to pay $140 million in cash upon the approval of Evamist's new drug application.
Read more at Reuters.com Government Filings News
No comments:
Post a Comment